摘要:
目的 评价西米替丁佐助阿奇霉素治疗肺炎支原体感染(Mycoplasma pneumoniae infection,MPI)患儿的疗效。 方法 选择2006年10月~2009年10月在本院就诊的MPI患者80例,随机分组:40例为观察组,40例为对照组,对照组采用阿奇霉素治疗,观察组在予以对照组相同治疗方案的同时,给予西米替丁治疗。用药前和1个疗程后分别检测外周血嗜酸性粒细胞(EOS)和总IgE(T-IgE)并,治疗后评定疗效。 结果 观察组治愈率为60.00%明显高于对照组的治愈率37.50%,具有统计学意义(P<0.05);观察组在用药前和1个疗程后EOS水平显著下降(P＜0.001),对照组EOS水平也下降,但与治疗前比较差异不显著(P>0.05),两组T-IgE水平基本无变化。不良反应:观察组发生胃肠道反应和皮疹各1例;对照组发生胃肠道反应3例、皮疹2例,两组不良反应率差异不显著(P>0.05)。 结论 西米替丁佐助阿奇霉素治疗MPI患儿不但疗效佳,而且也相对安全,建议临床进一步推广。
Abstract:
Objective To evaluate the efficacy and safety of cimetidine on Mycoplasma pneumoniae infection. Methonds 80 MPI patients were selected and randomized into the observation group and the control group averagely. The two groups were treated with azithromycin, while the observation group was given cimetidine additionally. Peripheral blood eosinophils (EOS) and total IgE (T-IgE) were detected before and after the treatment which were used to evaluated the effects of cimetidine. Results The cure rate of observation group was 60.00%s and significantly higher than that of the control group which was 37.50% There was statistically significant of the cure rate (P<0.05, see Table 1) between two groups. The EOS level of the observation group decreased significantly after a course of treatment (P<0.001, see Table 2), the EOS level of the control group also decreased but had no significant difference (P>0.05) with the level before treatment. T-IgE level of two groups nearly had no change. The observation group occurred 1case of rash and 1 case of gastrointestinal reaction. The control group occurred 3 cases of gastrointestinal reactions and 2 cases of rash. The adverse reaction rate of two groups had no significant difference (P>0.05). Conclusion Cimetidine for adjuvant treatment of MPI with azithromycin is efficiency and safety which should be recommended in clinic.
点击查看大图
下载:
